Momentum Trades

MomentumOptionsTrading.com Weekly Wrap for 1/12/2014

MomentumOptionsTrading.com Weekly Wrap for 1/12/2014

11:30pm (EST)

 

1.  Market Summary 

2.  Discovery Laboratories (DSCO) has a Bright Future

3.  Earnings

4.  Weekly Wrap Portfolio Update 

5.  Week Ahead

 

(To view the charts, please log into the Members Area and go to the Weekly Wrap Premium section.)

 

= = = = = = = = = = = = = = =

 

1.  Market Summary  

“The bulls enjoyed a sweet December as the Dow gained 490 points, or 3%; the S&P 500 soared 43 points, or 2%; the Nasdaq jumped 117 points, or nearly 3%; the Russell 2000 added 21 points, or 2%.

The final numbers for 2013 are impressive:  The Dow was up 3,472.56 points, or 26.5%; the S&P 500 surged 422.17 points, or 29.6%; the Nasdaq zoomed 1,157.08 points, or 38.3%; the Russell 2000 rocketed 314.29 points higher, or 37%.

Other sectors that did well include the S&P Spiders Biotech Index (XBI, $130.42, down $0.42) as it roared 50% higher:

GOLD11214

The theory is if stocks fail to rally during the holiday season, it often foreshadows a difficult year ahead for the market.  In some cases it could signal the start of an outright bear market. The S&P’s 3-point pop was positive but not much to write home about.

Gold fell 28% in 2013 after finishing just above the $1,200 level.  The yellow-metal tested a low of $1,181.40 in late December nearly fell into our yearend $1,175-$1,150 target zone from July.

GOLDb11214

Silver tested a low of $18.72 in late December and came with a buck and change of triggering our yearend target of $17.50.

Silver11214

Both Gold and Silver may have made short-term and possibly longer-term bottoms but any closes below the December lows will rekindle our lower-end price targets.

First Five Days of January are another important market tell and usually dictate how January might play out.  The first two days of 2014 are favoring the bears so the bulls will need to get off to a good start on Monday.

If the market is up over the first five trading days of the New Year, it often leads to more gains for the rest of the year.  Since 1950, when the market rose during the first five trading days, the S&P 500 went on to post full-year gains 85% of the time.

However, if the market trades lower over the first five trading days, it can be a good tell on how the year might finish by yearend.  Since 2000, the market has began the year lower five times.  In the years 2000, 2001, 2005, 2007 and 2008, the average loss for the S&P 500 was -11% following a lower first five trading days of the year.  If the bulls don’t rebound by Wednesday, they could have a hard time with history class in 2014.

The market will have plenty of news to trade on this week as earnings season gets underway and with Friday’s Nonfarm Payroll report.  We have listed the major companies reporting this week in our Earnings section of the Weekly Wrap but we will likely wait until next week to trade options.

We wanted to cover our prior 15-year charts for all of the indexes this week as well as we showed you the near-term charts, first, to give you a better view of where the indexes could be headed while showing new subscribers how we came up with our Price Targets.  We also like to wait until January finishes up before making our yearend predictions and we do want to show you last year’s chart for the Dow (and other indexes) as we were probably THE ONLY newsletter that predicted a 3,000 point gain for the blue-chips.  The index cleared this level mid-November and we said a run to 16,500-16,600 could come on fluff.

DOW11214

Here were our thoughts in the February 4, 2013 Weekly Wrap:

we expect maybe another 2% rise over the next few weeks, followed by a 5%-10% dip by April.  By then, we should know if the economy is “growing” or “stimulating” the way the zombies expect.

The one aforementioned sentence we want to remind you of this:

“The gains can be even staggering during post-election years as some periods have seen the market move 20% higher.”

A less than bullish, but still double-digit gains from here would be Dow 15,400; S&P (500) 1,650; Nasdaq 3,500; Russell (2000) 1,000 for 2013.  These targets are roughly 10% from current levels with some adjustments.

To get to our 2013 yearend targets, we took all of the bullish (and bearish) factors and split the difference of an advance of 10%-20% higher along with the price channels we have drawn for you.

Now for the drumroll…

Dow 16,000; S&P (500) 1,700; Nasdaq 3,800; Russell (2000) 1,025 

(END)’’ 

Final 2013 Results:  Dow 16,576; S&P 1,848; Nasdaq 4,176; Russell 1,163. 

Here was our chart work for the S&P and we penciled-in a rise to 1,700:

SPX11214

Here was our chart work for the Nasdaq and 3,800:

NAS11214

And one last chart on one of the BEST technical indicators, the S&P Volatility Index:

VIX11214

As you can see, we had factored in a move to 11-10 for the VIX and the 52-week low of 11.05 was hit by mid-March.  The recent low of 11.69 was triggered the day after Christmas.  The VIX is currently at 13.76 and this week or next could see a pop past 15 or a drop below 12.50 as we mentioned earlier.

We will talk more about the technical warnings we have been seeing over the past few weeks and months in our next issue of the Weekly Wrap and by then we will know how the first five days played out.  We will also take a peak at the longer-term charts as well.

Last week’s volume was weak so there is a chance buyers step in to start the week as most of Wall Street returns back to work following their long holiday vacations.  However, a weaker Monday needs to be watched along with Wednesday’s close to see if the bears are gaining momentum.  If they are, we can expect extreme volatility going forward as the bulls face reality.

Earnings, Fed Speak and Nonfarm payrolls will be the market moving headlines this week.  (from 1/5/2014 Weekly Wrap…)

The bulls tried to regain some momentum to start the week but after an opening pop the indexes dropped to close in negative territory on Monday.  It was the third-straight session of mixed to lower action but the bulls rebounded on Tuesday to push resistance.  Wednesday was a back test to support after the Fed minutes were released and Thursday was a flat day ahead of the Nonfarm Payrolls report.  Despite the disappointing number, the bulls rallied as the Fed may have been put on hold to further quantitative easing cuts.  (continued…)

The Dow slipped 7 points, or 0.05%, to finish at 16,437 on Friday.  The blue-chips traded to a high of 16,532 to start the week but finished lower 16,405.  Tuesday’s run to 16,562 and close at 16,530 looked promising but the bulls needed to clear 16,600 to get new all-time highs.  Wednesday belonged to the bears as the index traded in negative territory throughout the session before bottoming at 16,416 and ending at 16,462. The pop to 16,525 on Thursday quickly faded as the Dow fell below 16,400 to 16,378 before ending at 16,444.  Friday’s low reached 16,379 after an opening pop to 16,487.  We have been mentioning support at 16,400-16,350 for a few weeks now and this level held with a possible short-term “double-bottom” that came within a point of each other to end the week.  If 16,375 fails to hold there could be risk down to 16,200-16,000 and time to look at put options.  The lower highs are a concern but the blue-chips are exactly 1% away from tripping 16,600.  A close above this level would get our extended targets of Dow 16,800-17,000 in play.  For the week, the Dow fell 33 points, or 0.2%, after starting at 16,470 and is down 140 points, or 0.8%, for 2014.

Dowb11214

The S&P 500 added 4 points, or 0.2%, to settle 1,842.  The index came into the week needing to hold 1,825 on any pullback and this level was tested on Monday with the dip to 1,823 and close at 1,826.  Tuesday was an all green session as the index reached 1,840.10 but was unable to hold this level.  Wednesday’s peak reached. 1,840.02 before a half-point loss to 1,837.49.  The index closed exactly between bullish (1,850) and bearish territory (1,825) with Thursday’s action ending the same way with a half-point close above 1,838.  Friday’ s high reached 1,843 on the open before a dip to 1,832.  We talked all week about a bullish close above 1,840 could get 1,850 and all-time highs in play again with fluff up to 1,875-1,900.  A close below 1,825 will likely lead to a test down to 1,810-1,800.  The S&P 500 came into the week at 1,831 and added 11 points, or 0.6%, by Friday’s close.  For the year, the index is down 6 points, or 0.3%.

SPXb11214

The Nasdaq gained 18 points, or 0.4%, to end close at 4,174.66.  The bulls needed to clear 4,150 or hold 4,100 on any dip below 4,125 and Monday’s low reached 4,103 after an opening pop to 4,139.  The close at 4,113 was slightly bearish but Tuesday’s rebound reached a peak of 4,158 with a close at. 4,153.  This let us know the rest of the week could be bullish but we mentioned the All Clear sign doesn’t come until the bulls hurdle 4,175.  The dip to 4,145 midweek was followed with a surge to 4,171 with a 12-pack finish to 4,166.  Thursday’s high reached 4,181 before a nasty fall to 4,142.70 but the close at 4,156 assured us the bulls weren’t going away.  The volatility was nerve racking but Friday’s low of 4,142.21 may have signaled a possible short-term bottom before the close at session highs and a half-point off 4,175.  A pop past this level will likely lead to 4,200 with a surge to 4,400-4,500 a possibility.  A close below 4,125-4,100 would be bearish for a back test to 4,000 – or worse.  The Nasdaq was at 4,131 and jumped 43 points, or 1%, and is off 2 points, or 0.05%, year-to-date.

NASb11214

The Russell 2000 advanced 6 points, or 0.5%, to end at 1,164.53.  The small-caps came into Monday’s session needing to hold 1,150 while a close above 1,160 would be bullish.  The index tested 1,159.85 before falling to 1,147 by the close.  Tuesday’s open at 1,150.86 was the low for the session with a surge to 1,160.02 and close at 1,157.  Wednesday action stayed between 1,150-1,160 before Thursday’s surge to 1,163 and close at 1,158.  Friday’s back test to 1,154 was as far as the bears got before the run to session highs into the close.  The Russell came into Monday’s open at 1,156 was up 8 points, or 0.7%, for the week and is down up a point, or 0.1%, YTD.

RUT11214

The S&P 500 Volatility Index ($VIX, 12.14, down 0.75) tanked 6% on Friday and ended below 12.50 – a very bullish sign.  The VIX came into the week at 13.76 and tested 14 on Monday before Tuesday’s trip to 12.16 and close at 12.92.  There was little action on Wednesday despite the Fed news as the VIX stayed in a tight range of 13.24-12.86.  Thursday’s rodeo was pretty much the same with a range of 13.26-12.83.  This was also a good sign for the bulls despite Wall Street’s worries over the Nonfarm Payroll report on Friday.  We talked about not flinching until the VIX close above 15 and we also said not to get giddy until the bulls got the VIX back below 12.50.  We have talked about the possibility of the VIX testing 11 and this could be the week.  A close back above 12.50 to start the week needs to be watched.

VIXb11214

Despite all the noise for a selloff, correction, or pullback, the bulls made a run at resistance and the top of the trading ranges.

The First Five Trading Days were bearish as the bulls failed to rebound from a 3-day selloff to start the year.  The theory is that if the First Five days are up, the market usually ends higher in January and so goes the year.

The Dow dropped 114 points; the S&P 500 and Nasdaq fell 11 points apiece; and the Russell 2000 gave back a 6-pack for the First Five day run.  The Santa Rally wasn’t impressive so this is already 2 strikes against the bulls.

The talking heads and market pros will likely ramble on about the First Five days after the fact and may mention there is an 80% chance the market ends lower in January and possibly for the year.  While we have discussed this possibility from a historic standpoint, there also means there is still a 20% chance the market finishes 2014 higher and there is still 2 weeks of trading left.

We mentioned since 2000 when the First Five day were lower, the average loss on the S&P 500 was -11% following a lower First Five trading days of the year.  This would put the S&P at 1,665 by yearend.

We like to predict where the market is headed for the year in early February and this is something to keep in mind but bullish signs are appearing for a continued run higher before an impending pullback.

The Russell 2000 ended at an all-time closing high and the Nasdaq is within 2 points of another 13-year high.  The VIX is back below 12.50 and we have talked about a possible test to 11 and the 52-week low with an outside chance of a dip to the single-digits.

The Dow Transportation Average ($TRAN, 7,466, up 86) are also pushing fresh all-time highs despite the Dow lagging and usually is a good sign the blue-chips will reverse course and follow at some point.  The Transports were up nearly 2% for the week.

TRAN11214

Earnings season heats up this week and the Financial stocks will be the main focus.  Nearly all of the heavy-hitters report their numbers this week and the bulls have been waiting for a breakout to new highs.  The Financial Spiders (XLF, $22.09, up $x) are pushing fresh peaks and we talked about a run to $22 coming back in November.

XLF11214

Here were our thoughts from our November 17:

“We mentioned on Friday the Financial sector was showing some strength as we noticed a number of our favorite banking stocks getting pops.  It could be time for us to enter another Bank of America (BAC, $14.32, up $0.52) trade as shares could be on the verge of a breakout if the sector itself can regain some momentum.  The 52-week peak for BAC is just north of $15 and we have been riding shares higher from $5 for 2 years with Weekly Wrap recommendations.

The Finance Spiders (XLF, $20.86, up $0.28) are the best way to get an overall snapshot of the sector and it’s no secret they have been underperforming the broader market since peaking over a month ago.  We wanted to do some homework before playing a possible breakout and buying options on Friday and here is our analysis.

After clearing resistance at $20 in mid-October, the index failed to hold the breakout and was making lower lows before Friday’s rebound.  The XLF tested a low of $19.48 in early October and zoomed over 10% before the false breakout at resistance and a test to $21.  The 50-day MA has easily held and the chart shows the Spiders now dancing with the 20-day MA. The huge move on Friday reversed a week of losses and another run past $20 could lead to $22-$23” (END)

Companies have been lowering estimates for the upcoming earnings season by an 11-to-1 clip so there won’t be too many upside surprises and plenty of disappointments.  However, the bar is so low a snake could slither over it and most companies should match estimates with continued cost-cutting but revenues will be what’s important.

This is also option expiration week so there will be added volatility going into Friday’s close as traders battle over strike prices.  History favors the bulls but in recent years the bears have held the advantage as the Dow has ended option expiration week lower 9 of the past 15 years with an average loss of -1.4%.

The Dow also had its first negative Monday/ Friday close since November.  Although the losses were minor, the red days could mean something if the bulls fall into a hole to start and end the week.

The market has been in this exact same spot for over a year as we witnessed countless times in 2013 where Wall Street got it wrong betting on a pullback.  The same scenario is playing out again and usually when too many people are leaning on one side of the boat it usually tips over.

While we do respect the bears and a possible pullback, it may come later rather than sooner the longer support holds.  Either way, we are prepared for it as we have outlined crucial downside targets to watch for.  Until then, the bullish trend continues to be our friend.

As we head to press, futures are showing a slightly lower open to start the week:  Dow futures are down 31 points to 16,350 while the S&P 500 futures are lower by 3 points to 1,834.  The Nasdaq 100 futures are off 7 points to 3,554.

 

= = = = = = = = = = = = = = =

 

2.  Discovery Laboratories (DSCO) has a Bright Future 

By Michael Bryant

 

Key of Technicals Used In Following Article

Charta8512

Discovery Laboratories (DSCO, $2.43, down $0.04) seems to be making a comeback after the years of falling.

Charta11214

Pulmonary surfactant is a complex lipoprotein composed of 6 phospholipids and 4 Apo proteins.  It usually contains 70-80% phospholipids, 8-10% protein, and 10% lipids, primarily cholesterol.  Its primary role is to reduce surface tension in the lung, which prevents the collapse of the alveoli (breathing sacs) and helps to keep them open.  It also promotes gas exchange and reduces the effort needed to expand the lungs, thus reducing the work of breathing.

Cochrane developed a synthetic pulmonary surfactant, the peptide KL4 (or sinapultide).  KL4 consists of 21 amino acid residues where “K” is the amino acid lysine and “L” is the amino acid leucine.  Lysine plays a major role in calcium absorption, building muscle protein, recovering from surgery or injuries, and production of hormones, enzymes, and antibodies.  Leucine is used in the liver, adipose tissue, and muscle tissue.  Both are essential amino acids, and thus cannot be produced by most vertebrates.  The surfactant looks like KLLLLKLLLLKLLLLKLLLLK.  It is engineered to mimic the essential properties of human SP-B, the most important surfactant protein for lowering surface tension and promoting oxygen exchange.

Using the KL4 Technology, Cochrane led research on the development of lucinactant, trade name Surfaxin.  The liquid drug was designed not cause an immune reaction when injected directly into the lungs of premature infants.  In trials, much of the infants’ impaired lung functions would then be restored within hours after birth.  At the time, surfactants used to treat RDS infants were derived from cow and pig lungs and had multiple side effects.  Further, they were expensive, potentially damaging to the lungs, produced negative immune reactions, and could not be produced in sufficient quantities to meet demand.

The KL4 Technology and Surfaxin were further developed at Ortho-McNeil Pharmaceutical, a subsidiary of Johnson & Johnson (JNJ).  Dr. Robert Capetola was director of experimental therapeutics there till 1996, when he negotiated the exclusive license to the KL4 Technology and the drug.  He formed Acute Therapeutics (ATI) and served as Chairman and CEO before reverse merging Acute with Discovery Laboratories, a Nasdaq-listed biotechnology company which Capetola had co-founded on November 6, 1992.

Getting approval from the European Medicines Evaluation Agency (EMEA) to market Surfaxin for use in preventing RDS in infants born prematurely went smoothly.  The agency accepted the drug’s Marketing Authorization Application (MAA) on October 27, 2004.  However, getting FDA approval was much harder, facing rejection four times.

  • On April 14, 2004, the company filed a New Drug Application (NDA) to the FDA to market Surfaxin.  Two positive Phase III clinical trials showed Surfaxin’s superiority to Exosurf, a non-protein synthetic surfactant, and Surfaxin’s non-inferiority to Curosurf, a pig-derived surfactant and the leading surfactant used in Europe.  On March 6, 2005, the company received a letter from the FDA which did not require additional preclinical or clinical trials for final approval but asked for finalizing labeling and correcting previously reported manufacturing issues. 
  • On July 29, 2005, the company filed a response to the FDA’s letter to market Surfaxin after it made adjustments.  But on March 5, 2006, it again received a letter from the FDA, this time asking for further tightening of active ingredient and drug product specifications and related controls.  
  • On November 1, 2007, after completing six-month stability study, the company sent another response to the FDA’s letter to market Surfaxin.  But again, the FDA shot the drug down on May 2, 2008. 
  • On October 17, 2008, the company tried again after completing more quality control test. But on April 20, 2009, the FDA again rejected approval of Surfaxin.  The agency questioned the drug’s quality through its shelf life. 

Finally on March 6, 2012, the FDA approved Surfaxin.  A study completed on September 22, 2010 demonstrated that lung function with use of Surfaxin compared favorably to Curosurf.  Additionally, pulmonary distribution of surfactant was significantly improved with Surfaxin when compared with that of Curosurf.

The earlier an infant is born, the less developed the lungs are and the higher the risk of RDS. Most cases are seen in infants born before 28 weeks. It is very uncommon in infants born full-term (at 40 weeks).  About 90,000 infants are born prematurely in the U.S.  The worldwide market is estimated at $1 billion.  The company expects Surfaxin to reach annual sales of $50 million to $75 million.  Alternatives include Abbott Laboratories’ (ABT) Suvanta, Italian drug giant Chiesi Farmaceutici’s Curosurf, and privately-held Ony’s Infasurf, which are all animal-based products.  Exosurf developed by GlaxoSmithKline (GSK), is no longer marketed.  It is estimated that Surfaxin could capture 40% of the infant RDS market in the United States by 2016.

However, it was not until November 8, 2013 that the company launched Surfaxin commercially in the United States.  On February 13, 2013, the company signed a secured loan agreement with Deerfield Management, L.P.  Under the terms, Deerfield committed to give $30 million in 2013, $10 million immediately following execution of the agreement and $20 million upon the first commercial sale of Surfaxin.  Upon receipt of the $20 million in early December 2013, the company issued warrants to Deerfield for approximately 4.7 million shares at an exercise price of $2.81 per share.

Chartb11214

To expand Surfaxin to treat older patients and other diseases, such as cystic fibrosis and acute asthma, the company developed Aerosurf, an aerosolized KL4 surfactant drug-device product.  Because it is aerosolized, the surfactant is freeze-dried.  This gives it a long shelf life and can make it inexpensive to produce.  Aerosurf has completed pilot Phase II clinical trials for the prevention of RDS in premature infants with positive results.

The table below shows the three ongoing trials using Surfaxin and Aerosurf.

Chartc11214

The capillary aerosol generator (CAG) is part of its Afectair aerosolized drug delivery development program. The CAG has been designed to produce high volume, low-velocity aerosolized KL4 surfactant for intra-pulmonary delivery for the treatment of RDS in premature infants.

The company has no revenue or earnings.  Nor does it have any public pure-play competitors.

Chartd11214

At $2.43, the stock is way below its low target of $5.00 made by the 3 analysts recorded by Thomson/First Call.  Median and high target is $6.00, and mean target is $5.67.  Using a scale of 1.0 as a strong buy and 5.0 as a sell, the average rating of the stock was 1.7, unchanged from a week ago.

 

Current Month

Last Month

Two Months Ago

Three Months Ago

Strong Buy

1

1

1

1

Buy

2

1

2

2

Hold

0

0

0

0

Underperform

0

0

0

0

Sell

0

0

0

0

Charte11214

Chartf11214

= = = = = = = = = = = = = = =

 

3.  Earnings  

The companies in BOLD, we are looking at as possible trades and we may list call or put options on them in our Daily Newsletter.  If they become official recommendations, we sent out Trade Alerts or include them in our 9am and 1pm updates that come out during the week (Quotes are from 1/10/14 close)

By Catherine Tierney

 

Monday

Adams Express (ADX), Advaxis (ADXS), American Airlines Group (AAL), Amgen (AMGN), Century Bancorp (CNBKA), Charles Schwab (SCHW), Community Trust Bancorp (CTBI), Fidelity Southern (LION, First Bancorp (FNLC), First Horizon National (FHN), HB Fuller (FUL), Interactive Brokers Group (IBKR), Limoneira (LMNR), LiveDeal (LIVE), M&T Bank (MTB), Majesco Entertainment (COOL), Pacific Continental (PCBK), People’s United Financial (PBCT), Pure Cycle (PCYO), Sirius XM (SIRI), Wendy’s (WEN),  Union Bankshares (UNB), Wintrust Financial (WTFC)

 

Tuesday 

Commerce Bancshares (CBSH), JPMorgan Chase (JPM), Linear Technology (LLTC), Rocky Mountain Chocolate Factory (RMCF), SemiLEDs (LEDS), Washington Federal (WAFD), Wells Fargo (WFC)

 

Wednesday

Bank of America (BAC), Boston Private Financial Holdings (BPFH), Clarcor (CLC), CSX (CSX), Fastenal (FAST), Kinder Morgan (KMI), Kinder Morgan Management (KMR), MB Financial (MBFI), Plexus (PLXS), WNS Holdings (WNS)

 

Fastenal (FAST, $47.70, up $1.11)

February 50 calls (FAST140222C00050000, $0.75, up $0.25)

February 45 puts (FAST140222P00045000, $0.85, down $0.25)

Thoughts:  Earnings are due out Wednesday morning before the opening bell with a conference call at 10:00am (EST).

The company lowered guidance in December by a nickel and expects to earn 36 cents a share versus a prior forecast of 41 cents a share.  Shares fell from $48 to $44 on the news and the company has missed revenue estimates the past 3 quarters.

The recent break above the downtrend channel stalled at the 100-day MA but a close above $48 ahead of earnings might be bullish.

An earnings miss is not likely since the company guided but if revenue comes up short, shares could fall below $45.

While we are more BEARISH than bullish on the stock, a strangle trade with these options might be the best bet.  If the market breaks down this week, we could use the puts as a possible trade.

If the Financial stocks breakout and the market makes a run to news highs, the calla could do well as a move past $50 could be in the works.

With the straddle trade, a pop past $51.50-$52 or a plunge to $44-$43.50 should be enough of s move to make the trade profitable for a nice double-digit return.

FAST11214

Thursday

American Express (AXP), Associated Banc (ASBC), Bank of Ozarks (OZRK), BB&T (BBT), BlackRock (BLK), Capital One Financial (COF), Citigroup (C), First Republic Bank (FRC), Goldman Sachs Group (GS), Huntington Bancshares (HBAN), iGATE (IGTE), Intel (INTC), PNC Financial Services Group (PNC), PPG Industries (PPG), PrivateBancorp (PVTB), Skyworks Solutions (SWKS), SLM (SLM), Taiwan Semiconductor (TW), UnitedHealth Group (UNH), Westamerica Bancorporation (WABC)

 

Skyworks Solutions (SWKS, $27.75, up $0.03)

February 30 calls (SWKS140222C00030000, $0.60, up $0.05)

February 31 calls (SWKS140222C00031000, $0.40, up $0.05)

Thoughts:  Earnings are due out after the close on Thursday so any trade need to be in by then.

The company is expected to earn 66 cents a share on revenue of $500 million.  Skyworks has beat estimates the past 4 quarters by a 2 cents last time out and by a penny the previous 3.

Of the 15 suit-and-ties that cover the stock, the high estimates is 66 cents with the low estimates coming in at 65 cents.  If the company beats on the top and bottom lines there could be a few upgrades on the stock.

In July, shares moved from $22.45 to $23.89 after earnings and traded to a high of $24.94 intraday.  This represented more than a 10% pop and what we are looking for when trading earnings.

In late October, the stock jumped from to $24.48 to a high of $25.80 after the company reported their numbers and kissed an intraday high of $26.30.  This was an 8% pop.

A 10% move to the upside from current levels will get $30 in play.  The 20-day MA is at $27.84 and move above $28 into earnings could be a good sign a pop into the $30’s is coming.  Support is at $27.50 but an earnings miss will likely get $27-$26 in play.

Shares have been in a tight trading range for 6 weeks and the longer a stock is range bound, the breakout or breakdown tends to be greater.

The company guided analysts to their current forecast when he reported last time out.  We doubt they will miss estimates since they provided them.  However, if they sandbagged their forecast and come in with a 2-3 cent beat, shares should rally.

We could use the January call options but they expire on Friday.

SWKS11214

SLM (SLM, $26.82, up $0.19)

February 27 calls (SLM140222C00027000, $0.57, up $0.11)

Thoughts:  Shares reached a fresh 52-week peak of $26.86 on Friday and the company reports earnings on Thursday.  We aren’t thrilled with a sector with $1 trillion in student loan debt but shares are in an uptrend and are breaking out to new highs.

These options were active on Friday and are cheap enough for a possible trade on Wednesday.  The company is expected to earn 73 cents a share on $673 million in revenue.

In November, SLM said it would recognize a gain of 14 cents to earnings after the sale of all of its assets of its Campus Solutions business to Higher One Holdings completed.  We aren’t sure if Wall Street has these numbers built-in and if they don’t it will look like a massive earnings beat.

SLM11214

UnitedHealth Group (UNH, $74.70, down $1.38)

February 77.50 calls (UNH140222C00077500, $1.15, down $0.70)

Thoughts:  Shares could make a run to $80 over the near-term on a good earnings report.  Shares recently touched a 52-week high north of $77 but are in the midst of a back test to support at $74 and the 20-day MA.  If shares can hold this level into earnings, we could go long with these calls but a break below $73.50 ahead of earnings would be bearish and have us looking at put options.  Earnings are due out on Thursday.

UNH11214

Friday

Bank of New York Mellon (BK), Clubcorp Holdings (MYCC), Comerica (CMA), General Electric (GE), Home BancShares (HOMB), Morgan Stanley (MS), Schlumberger (SLB), SunTrust Banks (STI), Tessco Technologies (TESS), Webster Financial (WBS)

 

Schlumberger (SLB, $88.17, up $1.09)

February 90 calls (SLB140222C00090000, $1.65, up $0.55)

February 82.50 puts (SLB1402220082500, $0.83, down $0.36)

Thoughts:  Earnings are due out before Friday’s open.  Shares are near their uptrend line and a break above this level will get the $90’s in play.

SLB11214

= = = = = = = = = = = = =

 

4.  Weekly Wrap Covered Call Portfolio Update (Closing prices as of 1/10/14)

Our Weekly Wrap Closed Trade Track Record for 2014 is 2-0 (87-7, overall since the start of 2011). 

Special Notice:  We closed Exact Sciences (EXAS, $13.25, up $0.39) last week for a 7% profit.  We could have an upcoming trade in our Daily on near-term options as we have said shares could run past $15 and up to $20.

EXAS11214

 

Current Trades

Discovery Laboratories (DSCO, $2.43, down $0.04) Stock Trade

Original Entry Price:  $2.42 (1/7/14)

Lowered Price from Selling Options:  $2.42

Exit Target:  $4.50-$5

Return:  0%

Stop Target:  $1

Discovery Laboratories (DSCO, $2.43, down $0.04) Covered Call Stock/ Option Trade

Sold April 3 calls (DSCO140419C00003000, $0.25, flat)

Original Entry Price:  $2.42 (1/7/14)

Lowered Price from Selling Options:  $2.17

Exit Target:  $4.50-$5

Return:  12%

Stop Target:  $1

Action:  Shares traded to a high of $2.52 on Friday and the next wave of resistance is at $2.60.  If cleared, a run to $3 could be in the works.  Support is at $2.27-$2.20 and the 20-day and 50-day Moving Averages, respectively. 

(See Aforementioned chart) 

On 1/7/2014 we recommended buying shares at $2.42 and selling the April 3 calls (DSCO140419C00003000, $0.25, flat) for 25 cents to lower our cost basis to $2.17.  If we are called away in mid-April at $3 the trade will make 39%. 

 

Opko Health (OPK, $8.63, up $0.20)

March 10 calls (OPK140322C00010000, $0.50, up $0.05) LEAP OPTION

Original Entry Price:  $0.70 (12/17/13)

Exit Target:  $1.40-$2.10

Return:  -29%

Stop Target:  None

Action:  A close above $8.70 and the 20-day MA would be bullish for a possible run to $9-$9.50.  A drop below $8 will likely lead to $7.50.

OPK11214

Ariad Pharmaceuticals (ARIA, $6.73, down $0.03) Stock Trade

Original Entry Price:  $4.95 (10/25/13)

Lowered Price from Selling Options:  $4.95

Exit Target:  $8-$10

Return:  36%

Stop Target:  $5.75, raise to $6.25 (Stop Limit)

Action:  Ariad fell below $7 to start the week and closed at $6.82 after testing a low of $6.59.  Near-term support at $6.50 held but a break below this level will likely lead to a test to $6 and the 20-day MA.  We have a $6.25 Stop Limit in place to protect profits.

ARIA11214

H&R Block (HRB, $30.30, up $0.27)

January 30 calls (HRB140118C00030000, $0.30, flat)

Original Entry Price:  $1.10 (11/5/13)

Exit Target:  $2.20, lower to $1.10 (Limit Order)

Return:  -45%

Stop Target:  None

April 32 calls (HRB140419C00032000, $0.90, up $0.10) LEAP Option

Original Entry Price:  $0.95 (11/5/13)

Exit Target:  $1.90+

Return:  -5%

Stop Target:  None

Action:  Set LIMIT ORDERS to close the January 30 calls at $1.10 or better. 

Shares finally cleared $29.50 and made a run past $30.  We said we needed a move past $30 to feel comfortable into this week and our breakeven point on the January 30 calls is at $31.10.  We have set a Limit Order to close them at $1.10 or better and we will be monitoring the trade to see if need to adjust upwards or cut losses to save some premium.

We have plenty of time for the April 32 calls to make us a profit and to offset some of the January 30 calls if we end up with a loss.

HRB11214

Millennial Media (MM, $7.46, up $0.21) Stock Trade

Original Entry Price:  $6.95 (10/25/13)

Lowered Price from Selling Options:  $6.95

Exit Target:  $14

Return:  7%

Stop Target:  $6

February 10 calls (MM140222C00010000, $0.20, flat) LEAP Option

Original Entry Price:  $0.50 (10/25/13)

Exit Target:  $1.00

Return:  -60%

Stop Target:  None

Action:  Shares traded to a high of $7.74 to start the week but finished just below $7.50 by Friday’s close.  Support is at $7.25 and there is risk down to $7 on a break below this level.  A close above $7.75 should lead to $8-$9.  We believe Millennial Media is a takeover target that could catch a bid from one of the bigger players in the game.

MM11214

Boston Scientific (BSX, $13.11, up $0.33) Stock Trade

Sell to OPEN? February 13 calls

Original Entry Price:  $12.29 (10/21/13)

Lowered Price from Selling Options:  $12.29

Exit Target:  $15

Return:  7%

Stop Target:  $10

January 13 calls (BSX140118C00013000, $0.25, up$0.05)

Original Entry Price:  $0.45 (10/21/13)

Exit Target:  $1.35

Return:  -44%

Stop Target:  None

Action:  Set LIMIT ORDERS to close the January 13 calls at 60 cents or better.

Shares made a run to a fresh 52-week peak of $12.55 on Monday after 2 brokerage upgrades.  Over 15,000 contracts traded on the January 13’s on Monday as open interest ballooned to nearly 25,000 contracts.  Oppenheimer jumped on our bandwagon again and upgraded the stock from Overweight to Equal Weight with a Price Target of $15 on acceleration and margin improvements in its cardiology division.  Morgan Stanley also upgraded the stock with the same ratings.

A push to $13 came midweek with a high of $12.93 and $12.87 before Friday’s surge past $13.  Our breakeven point on the January 13 calls is $13.45 so set limit orders to close the calls at 60 cents or better this week.  We will send out a Trade Alert when we take action.

BSX11214

Pizza Inn Holdings (PZZI, $8.00, up $0.02) Stock Trade

Original Entry Price:  $8.10 (10/11/13)

Lowered Price from Selling Options/ Dividends:  No options available

Exit Target:  $12+

Return:  -1%

Stop Target:  $7

Action:  Shares stayed below $8 to start the week after kissing a low of $7.96 but pushing $8.16.  There is risk down to $7.75-$7.50 on a break below the 100-day MA.  We would like to see a close above $8.25 and the 20-day MA over the near-term.  The symmetrical triangle is signaling a major breakout (or possible breakdown) is coming.

ALC Hospitality is the latest to join the Pie Five craze as they were awarded 38 franchises in December.  The units will be developed near Our Town in northern VA, Maryland and DC.  This gets the number of Pie Fie stores in development for 2014 to 150 and we love this stock as a long-term core holding.  This is our third trade on PZZI as we have been bringing you this story since shares were under $4.  It is not too late to get in as we have said the stock could run to $15-$20 over the next 12-24 months.  (Sonic, from our earnings section, was a good example on how shares moved from $10-$20 on strong growth and just matching earnings.)

PZZI11214

Aruba Networks (ARUN, $19.03, up $0.28) LEAP Option Trade

January 20 calls (ARUN140118C00020000, $0.10, flat)

Original Entry Price:  $1.45 (10/11/13)

Exit Target:  $2.90

Return:  -93%

Stop Target:  None 

Action:  Shares cleared $18.50 last week and offered us some hope of still making a profit.  However, we will need a run past $20 and up to $21.50 in order to break even.  We could have saved a little premium by closing the trade Friday but we have been riding the position for 3 months and would hate to close a possible winning trade.  We also realize the options could expire out-of-the-money but we don’t mind risking the $100 to see the trade through.  We will send out a Trade Alert if and when we take action by Friday’s close.

ARUN11214

Sonus Networks (SONS, $2.86, up $0.01)

Original Entry Price:  $3.73 (9/9/13)

Lowered Price from Selling Options:  $3.73

Exit Target:  $5

Return:  -23%

Stop Target:  $2.50

Action:  Support fell below support (now resistance) at $3 and $2.90 and a test to $2.75 could come over the near-term.

SONS11214

Galena Biopharma (GALE, $6.35, up $0.31)

Original Entry Price:  $2.12 (7/8/13)

Lowered Price from Selling Options:  $2.12

Exit Target:  $5

Return:  200%

Stop Target: $4.25, raise to $5.50 (Stop Limit)

Action:  Shares traded to a high of $5.24 to start the week and reached $5.59 during Tuesday’s session.  We said last week a pop to $7 could come and Wednesday’s surge to $6.84 made us look like a fortune teller as another brokerage decided to re-raise us with a $9 Price Target.  Well, we have been all over the GALE story for 2 years and the recent bandwagon upgrades have been great for the stock but we won’t have our thunder stolen as we re-upped our Price Target to $10.

We have a Stop Limit of $4.25 that we will raise to $5.50 in case there is a back test.  We also mentioned there was little analyst coverage on the Street but said the company was starting to get noticed.  Perhaps they are reading the Weekly Wrap but we will lock-in profits if $6 and then $5.50 fail to hold.

GALE11214

DryShips (DRYS, $3.86, down $0.06)

Original Entry Price:  $5.25 (1/3/11)

Lowered Price from Selling Options:  $4.60

Exit Target:  $6

Return:  -16%

Stop Target:  $4

Action:  We said there was further risk down to $4 and possibly $3.50 on a break below this level.  We were looking to get out of this trade at $5 but we missed that window of opportunity at the end of 2013.  We still like the trade and the recent volatility is disappointing but we believe this is a short-term dip before a run back above $4 and eventually to $5 will come over the next 3-6 months.

DRYS11214

Trades on HOLD (5):  AKS Steel Holding (AKS), Rambus (RMBS), Bebe Stores (BEBE), Vivus (VVUS), Dendreon (DNDN)

 

= = = = = = = = = = = = = = =

 

5.  Week Ahead 

Here is a chart of the events for the week ahead:

Ecocal11214

 

 

 

 

 

 

 

Scroll to Top